


SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/09	SERIAL NO. 09/765,151
 JUL 14 2003 JCA PATENT & TRADEMARK OFFICE		INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Gilbert R. Gonzales et al.	
		(37 CFR 1.98(b)) Use several sheets if necessary)		FILING DATE January 17, 2001	GROUP 3751

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
<i>ATL</i>	A.L	WO 0037114	06/29/00	International			N/A
<i>ATL</i>	A.M	WO 9917747	04/15/99	International			N/A
<i>ATL</i>	A.N	WO 9512812	05/11/95	International			N/A
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS.(Including Author, Title, Date, Place of Publication) - - - - -

A.R	Cerrato et al., <u>Marking of Naltrexone and Placebo Capsules with Riboflavin as an Indicator of Compliance</u> , Farmacia Clinica, Vol. 6, No. 10, 1989, pp. 758-760
A.S	Del Boca et al., <u>Assessment of Medication Compliance in Alcoholics Through UV Light Detection of a Riboflavin Tracer</u> , Alcoholism, Clinical and Experimental Research, United States, November, 1996, Vol. 20, No. 8, pp. 1412-1417
A.T	International Search Report, PCT/US02/01167, May 6, 2003.

EXAMINER	DATE CONSIDERED
<i>Anuradha Ramas</i>	<i>8/13/03</i>

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED

JUL 17 2003

TECHNOLOGY CENTER R3700